These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 31129384

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M, Uhara H, Koga H, Okuyama R.
    J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nivolumab plus ipilimumab in metastatic colorectal cancer.
    Gourd E.
    Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
    [No Abstract] [Full Text] [Related]

  • 6. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA.
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 9. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D.
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J.
    J Clin Oncol; 2019 Apr 10; 37(11):867-875. PubMed ID: 30811280
    [Abstract] [Full Text] [Related]

  • 11. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y, Iwanaga A, Kuwatsuka S, Okubo Y, Murayama N, Ishii N, Hashimoto T, Utani A.
    J Dermatol; 2018 Jan 10; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract] [Full Text] [Related]

  • 12. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A, Shah U, Khine H, Vandergriff T, Froehlich T.
    Melanoma Res; 2017 Apr 10; 27(2):171-173. PubMed ID: 28099367
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
    Page B, Borradori L, Beltraminelli H, Yawalkar N, Hunger RE.
    J Eur Acad Dermatol Venereol; 2018 Jul 10; 32(7):e256-e257. PubMed ID: 28430376
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
    Numata S, Iwata Y, Okumura R, Arima M, Kobayashi T, Watanabe S, Suzuki K, Horiguchi M, Sugiura K.
    J Dermatol; 2018 Jan 10; 45(1):113-114. PubMed ID: 28225147
    [No Abstract] [Full Text] [Related]

  • 17. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
    Bello-Chavolla OY, Cortes-Arroyo JE, Vargas-Vazquez A, Quiroz-Compean F, Leal-Gutierrez G, Barragan-Dessavre M, Martinez-Samano JE.
    Rev Neurol; 2018 Oct 01; 67(7):279-280. PubMed ID: 30232801
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T, Hiura A, Uehara J, Toyoshima R, Nakagawa T, Yoshino K.
    Eur J Dermatol; 2021 Oct 01; 31(5):662-664. PubMed ID: 34642136
    [No Abstract] [Full Text] [Related]

  • 20. Dual checkpoint inhibitor-associated eosinophilic enteritis.
    Yang J, Lagana SM, Saenger YM, Carvajal RD.
    J Immunother Cancer; 2019 Nov 15; 7(1):310. PubMed ID: 31730503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.